You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Pfizer’s abrocitinib scores another phase III win in atopic dermatitis

Pfizer’s investigational oral Janus kinase 1 (JAK1) inhibitor abrocitinib has scored positive top-line results in a phase III atopic dermatitis trial.